Advanced Enzyme Technologies Limited — Updates, 08-02-2025: Press Release

Advanced Enzyme Technologies Limited reported its financial results for the third quarter and nine months ended December 2024. For Q3 FY25, revenue stood at ₹1,691 million, reflecting a year-on-year growth of 5% and a quarter-on-quarter increase of 16%. EBITDA was ₹553 million with an EBITDA margin of 33%, consistent with the previous year's performance. However, PAT decreased by 9% to ₹389 million, and EPS was ₹3.37, down 10% YoY.

Operationally, the Bio-Processing segment excelled with a remarkable 91% growth compared to Q2 FY25, while Human Nutrition saw an 8% decline year-on-year. International sales increased by 23% from Q2 FY25, contributing 55% to total revenue. Looking forward, Advanced Enzymes aims to enhance its B2C initiatives, particularly in Human Nutrition, while pursuing product development and capacity enhancements across its divisions.

Investors should closely monitor the company’s strategic focus on expanding its offerings and market presence, underscoring a positive growth trajectory despite recent challenges in profitability.